KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Non-Current Debt (2016 - 2021)

Alnylam Pharmaceuticals (ALNY) has disclosed Non-Current Debt for 5 consecutive years, with $675.7 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Non-Current Debt rose 253.25% year-over-year to $675.7 million, compared with a TTM value of $675.7 million through Dec 2021, up 253.25%, and an annual FY2021 reading of $675.7 million, up 253.25% over the prior year.
  • Non-Current Debt was $675.7 million for Q4 2021 at Alnylam Pharmaceuticals, up from $191.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $675.7 million in Q4 2021 and bottomed at $30.0 million in Q4 2017.
  • Average Non-Current Debt over 5 years is $127.2 million, with a median of $30.0 million recorded in 2017.
  • The sharpest move saw Non-Current Debt tumbled 80.0% in 2018, then soared 253.25% in 2021.
  • Year by year, Non-Current Debt stood at $30.0 million in 2017, then changed by 0.0% to $30.0 million in 2018, then changed by 0.0% to $30.0 million in 2019, then soared by 537.59% to $191.3 million in 2020, then skyrocketed by 253.25% to $675.7 million in 2021.
  • Business Quant data shows Non-Current Debt for ALNY at $675.7 million in Q4 2021, $191.3 million in Q4 2020, and $30.0 million in Q2 2019.